COMMUNIQUÉS West-GlobeNewswire

Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis
24/04/2026
SANDWICH, United Kingdom, April 24, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive [...]
Geneva College of Longevity Science Launches the World’s First PhD in Longevity Sciences
24/04/2026
GENEVA and CONSTANȚA, Romania, April 24, 2026 (GLOBE NEWSWIRE) -- The Geneva College of Longevity Science (GCLS) today announced the launch of the world’s first PhD in Medicine with a specialization in Longevity [...]
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
Les 250 meilleurs spécialistes du cancer se réunissent en Belgique pour repousser les frontières de la protonthérapie
24/04/2026
IBA réunit les experts les plus renommés en protonthérapie venant des institutions de soins oncologiques les plus prestigieuses. Louvain-la-Neuve, Belgique, le 24 avril 2026 – IBA (Ion Beam Applications S.A., EURONEXT [...]
The top 250 cancer specialists converge in Belgium to push the frontiers of proton therapy
24/04/2026
IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
24/04/2026
“Totality of evidence” approach to evaluate SCENESSE® EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central [...]
Vistin Pharma ASA: First quarter 2026 financial results
24/04/2026
Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24 th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter revenue of MNOK 112 [...]
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
24/04/2026
Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing loss White Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/04/2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
24/04/2026
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results. Full Year 2025 [...]
Chemed Reports First-Quarter 2026 Results
23/04/2026
Full-Year Guidance Increased Due To: Strong VITAS Performance Re-purchase of 500,000 Shares in the Quarter Two Roto-Rooter Franchises Purchased for $20.6 Million CINCINNATI, April 23, 2026 (GLOBE NEWSWIRE) -- Chemed [...]
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
23/04/2026
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab [...]
SkinnyRx GLP-1 Claims Evaluated: Review Semaglutide & Tirzepatide Weight Loss Medication Options with Clinician-Guided Care
23/04/2026
Semaglutide and tirzepatide telehealth access, compounded GLP-1 program pricing, refund terms, and weight loss medication overview for 2026 Sacramento, CA, April 23, 2026 (GLOBE NEWSWIRE) -- The information below [...]
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
24/04/2026
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive [...]
Denta Biome Under Investigation: Adem Naturals Chewable Dental Tablets for Oral Health Care Support
23/04/2026
A 2026 informational overview of Denta Biome chewable dental tablets, oral postbiotic science, FabM enzyme research context, gum health and bad breath ingredient analysis, pricing structure, and consumer verification [...]
Trevi Therapeutics to Participate in Upcoming May Events
23/04/2026
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]

Pages